RxSight (RXST) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $30.3 million, a decrease of 14% year-over-year (YoY) from $35.3 million and down 10% from $33.6 million in Q2 2025.

LAL Revenue: $25.7 million from 26,045 Light Adjustable Lenses (LALs) sold, up 6% YoY but down 5% sequentially.

LDD Revenue: $3.2 million from 25 Light Delivery Devices (LDDs) sold, down 69% YoY and 38% sequentially.

Gross Margin: Improved to 79.9%, up from 71.4% YoY and 74.9% in Q2 2025.

Net Loss: GAAP net loss of $9.8 million ($0.24 per share), compared to a loss of $6.3 million ($0.16 per share) in Q3 2024. Non-GAAP net loss was $1.7 million ($0.04 per share).

Cash Position: $227.5 million in cash and short-term investments, unchanged from Q2 2025.

2Strategic Updates and Business Highlights

Strengthened commercial execution in the U.S. and initiated global expansion efforts, particularly in Asia and Europe.

Launched new practice development programs (MasterClass and Elevate) aimed at enhancing clinical engagement and optimizing LAL workflow.

Increased engagement with over 2,000 ophthalmologists, representing approximately 20% of U.S. cataract surgeons.

Focused on expanding the installed base of LDDs and enhancing the number of LAL procedures performed by existing customers.

Appointed an Executive Vice President of International to lead global expansion initiatives.

3Forward Guidance and Outlook

2025 Revenue Guidance: Narrowed to $125 million to $130 million, implying a YoY decline of 11% to 7%. Q4 revenue expected between $23 million and $28 million.

Gross Margin Guidance: Increased to 76% to 77%, up from previous guidance of 72% to 74%.

Operating Expenses: Expected to remain between $145 million and $155 million, reflecting a 7% to 14% increase YoY.

Anticipated sequential growth in LAL procedures, with a focus on optimizing existing accounts rather than solely relying on new LDD placements.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Significant drop in both LDD sales and overall revenue compared to previous periods.

Market Competition: Increased competition from new entrants in the premium IOL market, which could impact demand for LAL.

Reimbursement Pressure: Anticipated decline in Medicare reimbursement rates for cataract surgery in 2026 may further drive demand for premium IOLs but could also intensify competition.

Operational Adjustments: While the company is making strategic changes, the transition may take time to yield significant results, indicating potential short-term challenges.

5Notable Q&A Insights

Management emphasized the importance of LAL procedure volumes as a key metric for evaluating success and growth.

The company is focusing on increasing the number of active surgeons and optimizing LAL sales among existing practices.

Concerns were raised about the impact of new market entrants and declining reimbursement rates, but management believes the overall long-term demand for premium IOLs will remain strong.

The potential for LAL adoption among post-refractive and LASIK patients was highlighted as a significant growth opportunity.

Management reiterated their commitment to building a strong foundation for future growth through enhanced customer engagement and education initiatives. Overall, RxSight is navigating a challenging market environment while focusing on strategic growth initiatives and improving operational efficiencies.